Streetbeat News

Regulatory

VTAK

Catheter Precision has published results on the use of VIVO for non-invasive stereotactic radioablation in HeartRhythm Case Reports. This development could impact the medical device market, particularly in cardiac treatment technologies.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 12:42 pm

IVA

Inventiva has announced an abstract from its LEGEND Phase 2 trial, which evaluates the combination of Lanifibranor and Empagliflozin in treating NASH. This will be presented at the AASLD Liver Meeting 2024.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 12:40 pm

ENVX

EVGO

PLUG

JPMorgan analyst Bill Peterson recommends clean tech stocks Plug Power, EVgo, and Enovix as election season approaches. Plug Power and EVgo are seen as election-exposed plays, while Enovix is considered a safer hedge against election-related risks.

Portfolio Pulse from Surbhi Jain

October 21, 2024 | 12:35 pm

ICCM

IceCure Medical has received a Notice of Allowance from the U.S. Patent Office for its next-generation cryoablation system, which includes innovative technology for enhanced usability and cryogen integrity. The XSense system, already FDA-cleared, is set to address needs in the $1.67 billion global tumor ablation market.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 12:34 pm

DRTS

Alpha Tau Medical has been accepted into the FDA's Total Product Life Cycle Advisory Program Pilot, which could enhance its product development and regulatory strategy.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 12:32 pm

ABBV

AbbVie announced that nine Canadian provinces have accelerated public coverage for EPKINLY, a treatment for certain types of lymphoma. This expansion follows its initial listing in Ontario and Quebec.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 12:14 pm

LENZ

LENZ Therapeutics announced that the FDA has accepted its New Drug Application for LNZ100, a treatment for presbyopia. The FDA has set a target action date of August 8, 2025, and will not hold an advisory committee meeting.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 12:09 pm

AMRX

Amneal Pharmaceuticals' shares rose following FDA approval of its New Drug Application for Pyridostigmine Bromide Extended-Release Tablets.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 12:09 pm

AMRX

Amneal Pharmaceuticals has received FDA approval for its new drug, Pyridostigmine Bromide Extended-Release Tablets, designed for the U.S. Armed Services. This once-daily medication offers improved compliance over the current thrice-daily regimen.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 12:09 pm

MDGL

Madrigal Pharmaceuticals has completed enrollment for its MAESTRO-NASH OUTCOMES study, which evaluates resmetirom for treating compensated NASH cirrhosis. Positive results could lead to the first approved medication for this condition and support full approval for noncirrhotic NASH.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 12:08 pm